Genetic influences on smoking: Candidate genes

Environmental Health Perspectives

Volumn 106, Issue 5, 1998, Pages 231-238

  Rossing, Mary Anne ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Addiction; Dopamine; Genetic factors; Nicotine; Smoking

Indexed keywords

ALCOHOL; COCAINE; DOPAMINE; NICOTINE; NICOTINIC RECEPTOR; OPIATE;

ALLELE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; GENETIC ANALYSIS; HABIT; HUMAN; LIMBIC SYSTEM; NEUROPATHOLOGY; PERIKARYON; PERSONALITY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; TOBACCO;

EID: 0031867741     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106231     Document Type: Review

References (148)

1. Skaar KL, Tsoh JY, McClure JB, Cinciripini PM, Friedman K, Wetter DW, Gritz ER. Smoking cessation 1: an overview of research, Behav Med 23:5-13 (1997).
2. Pomerleau OF. Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence. Behav Genet 25:161-177 (1995).
3. Hughes JR. Genetics of smoking: a brief review. Behav Ther 17:335-345 (1986).
4. Carmelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking-a study of male twins. N Engl J Med 327(12):829-833 (1992).
5. Heath AC, Martin NG. Genetic models for the natural history of smoking: Evidence for a genetic influence on smoking persistence. Addict Behav 18:19-34 (1993).
6. Heath AC, Gates R, Martin NG, Meyer J, Hewitt JK, Neale MC, Eaves LJ. Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. J Subst Abuse 5:221-246 (1993).
7. Edwards KL, Austin MA, Jarvik GP. Evidence for genetic influences on smoking in adult women twins. Clin Genet 47:236-244 (1995).
8. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382:255-257 (1996).
9. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 6:243-251 (1996).
10. Nisell M, Nomikos GG, Svensson TH. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76:157-162 (1995).
11. Rose JE, Corrigall WA, Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 130:28-40 (1997).
12. Ascher JA, Cole JO, Colin JM, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401 (1995).
13. Vassout A, Bruinink A, Krauss J, Waldmeier P, Bischoff S. Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants. J Recept Res 13:341-354(1993).
14. Anonymous. Two products join ranks of smoking cessation treatments. Am J Health Syst Pharm 54:1478 (1997).
15. Goldman D, Lappalainen J, Ozaki N. Direct analysis of candidate genes in impulsive behaviours. Ciba Found Symp 194:139-154 (1996).
16. Comings DE. Genetic factors in drug abuse and dependence. NIDA Res Monogr 159:16-48 (1996).
17. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC. Smoking and major depression. A causal analysis. Arch Gen Psychiatry 50:36-43 (1993).
18. Swan GE, Carmelli D, Cardon LR. The consumption of tobacco, alcohol, and coffee in Caucasian male twins: a multivariate genetic analysis. J Subst Abuse 8(1):19-31(1996).
19. Austin MA, Newman B. Genetic influence on smoking. N Engl J Med 328(5):353 (1993).
20. Landry DW. Immunotherapy for cocaine addiction. Sci Am 276:42-45 (1997).
21. Di Chiara G, Imperato A, Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278 (1988).
22. Robbins TW, Everitt BJ. Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6:228-236 (1996).
23. 2-like dopamine receptor agonists. Science 271:1586-1589 (1996).
24. 2 dopamine receptor A1 allele. Nature Med 1:337-341 (1995).
25. Uhl GR, Gold LH, Risch N, Genetic analyses of complex behavioral disorders. Proc Natl Acad Sci USA 94:2785-2786 (1997).
26. Goldman D, Candidate genes in alcoholism. Clin Neuroscience 3:174-181 (1995).
27. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nature Genet 12:78-80 (1996).
28. Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nature Genet 12:81-84 (1996).
29. Dani JA, Heinemann S, Molecular and cellular aspects of nicotine abuse. Neuron 16:905-908 (1996).
30. Henningfield JE, Heishman SJ. The addictive role of nicotine in tobacco use. Psychopharmacology 117:11-13 (1995).
31. Clarke PBS. Mesolimbic dopamine activation-the key to nicotine reinforcement? Ciba Found Symp 152:153-168 (1990).
32. Giros B, Caron MG. Mofecular characterization of the dopamine transporter. Trends Pharmacol Sci 14:43-49 (1993).
33. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45:1041-1051 (1995).
34. Hellebrand W, Seidler A, Robre B-P, Vieregge P, Oertel WH, Goerg J, Nischan P, Schneider E, Ulm G. Smoking and Parkinson's disease: a case-control study in Germany. Int J Epidemiol 26:328-339 (1997).
35. Balfour DJ, Fagerstrom KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72:51-81 (1996).
36. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schyler D, Wolf AP, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733-736 (1996).
37. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, Shea C, Alexoff D, Shea C, MacGregor RR, Schyler D, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93:14065-14069 (1996).
38. Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol 1144:4-9 (1997).
39. Jonsson E, Sedvall G, Brene S, Gustavsson JP, Geijer T, Terenius L, Crocq M-A, Lannfelt L, Tylec A, Sokolof P, et al. Dopamine-related genes and their relationships to monoamine metabolites in CSF. Soc Biol Psych 40:1032-1043 (1996).
40. Geijer T, Jonsson E, Neiman J, Persson M-L, Brene S, Gyllander A, Sedvall G, Rydberg U, Wasserman D, Terenius L. Tyrosine hydroxylase and dopamine D4 receptor allelic distribution in Scandinavian chronic alcoholics. Alcohol Clin Exp Res 21:35-39 (1997).
41. Todd RD, Lobos EA, Parsian A, Simpson S, DePaulo JR, for the Bipolar Disorder Working Group. Manicdepressive illness and tyryosine hydroxylase markers. Lancet 347:1634 (1996).
42. de Castro IP, Santos J, Torres P, Visedo G, Saiz-Ruiz J, Llinares C, Fernandez-Piqueras J. A weak association between TH and DRD2 genes and bipolar affective disorder in a Spanish sample. J Med Genet 32:131-134 (1995).
43. Kawada Y, Hattori M, Fukuda R, Arai H, Inoue R, Nanko S. No evidence of linkage or association between tyrosine hydroxylase gene and affective disorder. J Affect Disord 34:89-94 (1995).
44. Souery D, Lipp O, Mahieu B, Mendelbaum K, De Bruyn A, De Maertelaer V, Van Broeckhoven C, Mendlewicz J. Excess tyrosine hydroxylase restriction fragment length polymorphism homozygosity in unipolar but not bipolar patients: a preliminary report. Biol Psych 40:305-308 (1996).
45. Thibaut F, Ribeye JM, Dourmap N, Meloni R, Laurent C, Campion D, Menard JF, Dollfus S, Mallet J, Petit M. Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia. Schizophren Res 23:253-264 (1997).
46. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE. Tyrosine hydroxylase polymorphism in familial and sporadic Parkinson's disease. Move Disord 9:337-339 (1994).
47. Leboyer M, Malafosse A, Boularand S, Campion D, Gheysen F, Samolyk D, Henriksson B, Denise E, des Lauriers A, Lepine J-P, et al. Tyrosine hydroxylase polymorphisms associated with manic-depressive illness. Lancet 335:1219 (1990).
48. Polymeropoulos MH, Xiao H, Rath OS, Merril CR. Tetranucleotide repeat polymorphism at the human tyrosine hydroxylase gene (TH). Nucleic Acids Res 19:3753 (1991).
49. Souery D, Lipp O, Mahieu B, Mendelbaum K, De Maertelaer V, Van Broeckhoven C, Mendlewicz J. Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes. Am J Med Genet 67:551-555 (1996).
50. Meloni R, Leboyer M, Bellivier F. Association of manicdepressive illness with tyrosine hydroxylase microsatellite marker. Lancet 345:932 (1995).
51. Ludecke B, Bartholome K. Frequent sequence variant in the human tyrosine hydroxylase gene. Hum Genet 95:716 (1995).
52. Kunugi H, Kawada Y, Tatsumi M, Sasaki T, Nanko S. Manic-depressive illness and tyrosine hydroxylase gene, Lancet 348:336 (1996).
53. Hitri A, Hurd YL, Wyatt RJ, Deutsch SI. Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol 17:1-22 (1994).
54. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-1106 (1992).
55. Sander T, Harms H, Podschus J, Finckh U, Nickel B, Rolfs A, Rommelspacher H, Schmidt LG. Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Biol Psychiatry 41:299-304 (1997).
56. Persico AM, Macciardi F, Genotypic association between dopamine transporter gene polymorphisms and schizophrenia. Am J Med Genet 74:53-57 (1997).
57. Cook EH, Stein MA, Karsowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL. Association of attentiondeficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993-998 (1995).
58. Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 11:195-200 (1994).
59. Plante-Bordeneuve V, Taussig D, Thomas F, Said G, Wood NW, Marsden CD, Harding AE. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 48:1589-1593 (1997).
60. Caporaso NE, Lerman C, Main D, Audrain J, Boyd NR, Bowman E, Shields P. The genetics of smoking: the dopamine receptor transporter (DAT) polymorphisms in a smoking cessation study [abstract]. Proc Am Assoc Cancer Res 38:166-169 (1997).
61. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69 (1992).
62. Strange PG. New insights into dopamine receptors in the central nervous system. Neurochem Int 22:223-236 (1993).
63. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmecol Sci 15:264-270 (1994).
64. Nakajima S. Subtypes of dopamine receptors involved in the mechanism of reinforcement. Neurosci Biobehav Rev 13:123-128 (1989).
65. Goetz CG. New strategies with dopaminergic drugs: Modified formulations of levodopa and novel agonists. Exp Neurol 144:17-20 (1997).
66. Cichon S, Nothen MM, Erdmann J, Propping P. Detection of four polymorphic sites in the human dopemine D1 receptor gene (DRD1). Hum Mol Genet 3:209(1994).
67. Liu Q, Sobell JL, Heston LL, Sommer SS. Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphisms but lack of functionally significant sequence changes. Am J Med Genet 60:165-171 (1995).
68. Cichon S, Nothen MM, Stober G, Schroers R, Albus M, Maier W, Rietschel M, Korner J, Weigelt B, Franzek E, et al. Systematic screening for mutations in the 5;-regulatory region of the human dopamine D-1 receptor (DRD1) gene in patients with schizophrenia and bipolar effective disorder. Am J Med Genet 67:424-428 (1996).
69. Sander T, Harms H, Podschus J, Finckh U, Nickel B, Rolfs A, Rommelspacher H, Schmidt LG. Dopamine D1, D2 and D3 receptor genes in alcohol dependence. Psychiatr Genet 5:171-176 (1995).
70. 1 receptor gene in addictive behaviors. Mol Psychiatry 2:44-56 (1997).
71. 2 receptor gene in alcoholism or schizophrenia. J Am Med Assoc 271:204-208 (1994).
72. 2 dopamine receptor missense variants. J Biol Chem 271:26013-26017 (1996).
73. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Mol Genet 6:577-582 (1997).
74. Kidd KK, Pakstis AJ, Castiglione CM, Kidd JR, Speed WC, Goldman D, Knowler WC, Lu R-B, Bonne-Tamir B. DRD2 haplotypes containing the taql A1 allele: implications for alcoholism research. Alcohol Clin Exp Res 20:697-705 (1996).
75. Noble EP. Alcoholism and the dopaminergic system: a review. Addict Biol 1:333-348 (1996).
76. Neiswanger K, Kaplan BB, Hill SY. What can the DRD2/alcoholism story teach us about association studies in psychiatric genetics? Am J Med Genet 60:272-275 (1995).
77. 2 receptor gene in samples of female and male alcoholics. Am J Med Genet 60:267-271 (1995).
78. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJH, Comings DE. Dopamine D2 receptor gene variants: Association and linkage studies in impulsive-addictive-compulsive behavior. Pharmacogenetics 5:121-141 (1995).
79. Berrettini WH, Persico AM. Dopamine D2 receptor gene polymorphisms and vulnerability to substance abuse in African Americans. Biol Psychiatry 40:144-147 (1996).
80. Finckh U, Giraldo-Velasquez MG, Pelz J, Otto G, Sander T, Schmidt LG, Rommelspacher H, Rolfs A. Dopamine D2 receptor gene (DRD2) haplotypes in Caucasians. Gene 179:251-255 (1996).
81. 2 receptor locus. Biol Psychiatry 34:204-209 (1993).
82. 2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48:648-654 (1991).
83. 2 dopamine receptor polymorphism and brain regional glucose metabolism. Am J Med Genet 74:162-166 (1997).
84. Noble EP, Lawford BR, Syndulko K. Bromocriptine in the treatment of alcoholics. Reply to letter. Nature Med 1:720-721 (1995).
85. Noble EP, St. Jeor ST, Ritchie T, Syndulko K, St. Jeor SC, Fitch RJ, Brunner RL, Sparkes RS. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypoth 42:257-260 (1994).
86. 2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 6:73-79 (1996).
87. 3 receptor and actions of substances of abuse. EXS 71:81-92 (1994).
88. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Honsson E, Sedvall G, Schwartz JC. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 2:249-256 (1992).
89. Durnay N, Thome J, Palomo A, Foley P, Riederer P, Cruz-Sanchez FF. Homozygosity at the dopamine D3 receptor gene in schizophrenic patients. Neurosci Lett 220:151-154 (1996).
90. Ebstein RP, Macciardi F, Heresco-Levi U, Serretti A, Blaine D, Verga M, Nebamov L, Gur E, Belmaker RH, Avnon M, et al. Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia, Hum Hered 47:6-16 (1997).
91. Kennedy JL, Billett E, Macciardi FM, Verga M, Parsons T, Meltzer HY, Lieberman J, Buchanan JA, Association study of the dopamine D3 receptor gene and schizophrenia, Am J Med Genet 60:558-562 (1995).
92. 4 receptors genes and alcoholism. Am J Med Genet 74:281-285 (1997).
93. Higuchi S, Muramatsu T, Matsushita S, Murayama M. No evidence of association between structural polymorphism at the dopamine D3 receptor locus and alcoholism in the Japanese. Am J Med Genet 67:412-414 (1996).
94. Gorwood P, Martres MP, Ades J, Skoloff P, Noble EP, Geijer T, Blum K, Neiman J, Jonsson E, Feingold J, et al. Lack of association between alcohol-dependence and D3 dopamine receptor gene in three independent samples. Am J Med Genet 60:529-531 (1995).
95. Freimer M, Kranzler H, Satel S, Lacobelle J, Skipsey K, Charney D, Gelernter J. No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. Addict Biol 1:281-287 (1996).
96. 4 receptor (D4DR) 16 amino acid repeat polymorphism and novelty seeking. Mol Psychiatry 1:388-391(1996).
97. Chang F-M, Kidd JR, Livak KJ, Pakstis AJ, Kidd KK. The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus. Hum Genet 98:91-101 (1996).
98. Chang F-M, Ko H-C, Lu R-B, Pakstis AJ, Kidd KK. The dopamine D4 receptor gene (DRD4) is not associated with alcoholism in three Taiwanese populations: six polymorphisms tested separately and as haplotypes. Biol Psychiatry 41:394-405 (1997).
99. Chang F-M, Kidd KK. Rapid molecular haplotyping of the first exon of the human dopamine D4 receptor gene by heteroduplex analysis. Am J Med Genet 74:91-94 (1997).
100. Di Bella D, Catalano M, Cichon S, Nothen MM. Association study of a null mutation in the dopamine D4 receptor gene in Italian patients with obsessive-compulsive disorder, bipolar mood disorder and schizophrenia. Psychiatr Genet 6:119-121 (1996).
101. 5 dopamine receptor gene. Hum Genet 92:633-634 (1993).
102. 5 dopamine receptor gene in schizophrenia: identification of a nonsense change and multiple missense changes but lack of association with disease. Hum Mol Genet 4:507-514 (1995).
103. 5 receptor gene promoter. Neurosci Lett 205:173-176 (1996).
104. n repeat at its gene locus in healthy individuals. Hum Genet 99:52-55 (1997).
105. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, Gogos JA. Genotype determing low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA 94:4572-4575 (1997).
106. Lachman HM, Papolos DF, Saito T, Yu Y-M, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyl- transferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 8:243-250 (1996).
107. Syvanen A-C, Tilgmann C, Rinne J, Ulmanen I, Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland. Pharmacogenotics 7:65-71 (1997).
108. Hoda F, Nicholl D, Benett P, Arranz M, Aitchison J, Al-Chalabi A, Kunugi H, Vallada H, Leigh PN, Chaudhuri KR, et al. No association between Parkinson's disease and low-activity alleles of catechol-O-methyltransferase. Biochem Biophys Res Comm 228:780-784 (1997).
109. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier DA. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease, Neurosci Lett 221:202-204 (1997).
110. 1947 Polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord 12:426-427 (1997).
111. Strous RD, Bark N, Woerner M, Lachman HM. Lack of association of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry 41:493-495 (1997).
112. Strous RD, Bark N, Persia SS, Volavka J, Lachman HM. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Res 69:71-77 (1997).
113. Daniels JK, Williams NM, Williams J, Jones LA, Cardno AG, Murphy KC, Spurlock G, Riley B, Scambler P, Asherson P, et al. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol-O-methyltransferase activity. Am J Psychiatry 153:268-270 (1996).
114. BEBCG (Biomed European Bipolar Collaborative Group). No association between bipolar disorder and alleles at a functional polymorphism in the COMT gene. Br J Psychiatry 170:526-528 (1997).
115. Gutierrez B, Bertranpetit J, Guillamat R, Valles V, Arranz MJ, Kerwin R, Fananas L. Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Am J Psychiatry 154:113-115 (1997).
116. Sobell JL, Lind TJ, Hebrink DD, Heston LL, Sommer SS. Screening the monoamine oxidase B gene in 100 male patients with schizophrenia: a cluster of polymorphisms in African-Americans but lack of functionally significant sequence changes. Am J Med Genet 74:44-49 (1997).
117. Coron B, Campion D, Thibaut F, Dollfus S, Preterre P, Sanglois S, Thierry V, Moreau, V, Martin C, Charbonnier F, et al. Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. Psychiatry Res 62:221-226 (1996).
118. Berlin I, Said S, Spreux-Varoquaux O, Launay J-M, Olivares R, Millet V, Lecrubier Y, Puech AJ. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 58:444-452 (1995).
119. Hotamisligil GS, Breakefield XO. Human monamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet 49:383-392(1991).
120. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 33:367-372 (1993).
121. Ho SL, Kapadi AL, Ramsden DB, Williams AC. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 37:403-405 (1995).
122. Costa P, Checkoway H, Levy D, Smith-Weller T, Franklin GM, Swanson PD, Costa LG. Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease. Am J Med Genet 74:154-156 (1997).
123. Meszaros K, Lenzinger E, Fureder T, Hornik K, Willinger U, Stompe T, Heiden AM, Resinger E, Fathi N, Gerhard E, et al. Schizophrenia and the dopamine-β-hydroxylase gene: results of a linkage and association study. Psychiatric Genet 6:17-22 (1996).
124. Wei J, Ramchand CN, Hemmings GP. A study of the relationship between the DBH activity in serum and a Mspl polymorphic site in intron 9 of the human DBH gene in schizophrenia. Schizophr Res 22:77-80 (1996).
125. Debruyn A, Souery D, Mendelbaum K, Mendlewicz J, Van Broeckhoven C. A linkage study between bipolar disorder and genes involved in dopaminergic and GABAergic neutrotransmission. Psychiatric Genet 6:67-73 (1996).
126. La Grange L, Jones TD, Erb L, Reyes E. Alcohol consumption: biochemical and personality correlates in a college student population. Addictive Behav 20:93-103 (1995).
127. Wei J, Xu H-M, Ramchand CN, Hemmings GP. Is the polymorphic microsatellite repeat of the dopamine βhydroxylase gene associated with biochemical variability of the catecholamine pathway in schizophrenia? Biol Psychiatry 41:762-767 (1997).
128. Hsiao JK, Potter WZ, Agren H, Owen RR, Pickar D. Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology 112:S76-S84(1993).
129. 2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet 74:65-72 (1997).
130. Rose JE. Nicotine addiction and treatment. Annu Rev Med 47:493-507 (1996).
131. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36:597-613 (1996).
132. Phillips HA, Muller JC. Short report on DNA marker at candidate locus. SSCP variants within the α4 subunit of the neuronal nicotinic acetylcholine receptor gene. Clin Genet 51:135-136 (1997).
133. Steinlein OK, Deckert J, Nothen MM, Franke P, Maier W, Beckmann H, Propping P. Neuronal nicotinic acetylcholine receptor α4 subunit (CHRNA4) and panic disorder: an association study. Am J Med Genet 74:199-201 (1997).
134. Weiland S, Steinlein O. Short report on DNA marker at candidate locus. Dinucleotide polymorphism in the first intron of the human neuronal nicotinic acetylcholine receptor a4 subunit gene (CHRNA4). Clin Genet 50:433-434 (1996).
135. Steinlein OK. Detection of a Cfol polymorphism within exon 5 of the human neuronal nicotinic acetylcholine receptor a4 subunit gene (CHRNA4). Hum Genet 96:130 (1995).
136. Nakajima M, Yamamoto T, Nunoya K-I, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Role of human cytochrome P4502A6 in c-oxidation of nicotine. Drug Metab Dispos 24:1212-1217 (1996).
137. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydrozylation in human liver microsomes. Biochemistry 29:1322-1329 (1990).
138. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J, Evans WE, Idle JR, Gonzalez FJ. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57:651-660 (1995).
139. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (1997).
140. Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E, Leathart J, Daly AK, Idle JR. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 343;62-63 (1994).
141. Benowitz NL, Jacob P, Perez-Stable E. CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics 6:239-242 (1996).
142. Bertilsson L, Dahl M-L Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 5(3):200-223 (1996).
143. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L Relationship between personality and debrisoquine hydroxyiation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrone P450206. Acta Psychiatr Scand 87:23-28 (1993).
144. Martinez C, Agundez JAG, Gsrvasini G, Martin R, Benitez J. Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 7:85-93 (1997).
145. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60:265-271 (1997).
146. Turgeon J, Debrisoquine metabolic ratio (DMR) distribution differs among smokers and non-smokers [abstract]. Clin Pharmacol Ther 57:150 (1995).
147. Cholerton S, Boustead C, Taber H, Arpanahi A, Idle JR. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics 6:261-263 (1996).
148. Garcia-Closas M, Caporaso N, Kelsey KK, Christiani DC. Association between CYP1A1 Msp 1 polymorphism and smoking in a control population: implications for the study of genetic effects on cancer risk [abstract]. Proc Am Assoc Cancer Res 38:211 (1997).